Cernostics: Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher Barrett's Esophagus Assay

(marketscreener.com) Pittsburgh, PA, Sept. 08, 2021 -- Cernostics, pioneer of the worlds' first precision medicine test to predict future development risk of esophageal cancer from Barrett's esophagus , TissueCypher® Barrett's Esophagus Assay, has become a participating provider for Geisinger Health Plan 's more than 550,000 plan...https://www.marketscreener.com/news/latest/Cernostics-Contracts-with-Geisinger-Health-Plan-to-Become-an-In-network-Provider-for-TissueCypher-B--36373270/?utm_medium=RSS&utm_content=20210908